Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $20.72

Key Points

• Analyst sentiment is mixed: Intellia Therapeutics has a consensus “Hold” rating from 23 brokerages, with five sell, eight hold, nine buy and one strong-buy recommendation. The average 12-month price target is $20.72.
• Shares opened at $11.42, well below the analyst target, with a market capitalization of approximately $1.60 billion. The stock has traded between $7.95 and $28.25 over the past year.
• Financial results remain weak: Intellia reported a quarterly loss of $0.80 per share and $7.66 million in revenue, down 46.4% year over year and below analyst expectations of $12.98 million. Institutional investors own 88.77% of the company.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-three brokerages that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.72.

A number of research analysts have weighed in on the company. Wedbush raised their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Wednesday, September 9th. Citizens Jmp reaffirmed a "market outperform" rating and set a $30.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Wolfe Research lowered shares of Intellia Therapeutics from a "peer perform" rating to an "underperform" rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Citigroup reaffirmed a "market outperform" rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Thursday.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. PNC Financial Services Group Inc. lifted its stake in Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company's stock worth $46,000 after purchasing an additional 948 shares in the last quarter. Wealthfront Advisers LLC grew its position in shares of Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company's stock valued at $185,000 after purchasing an additional 1,018 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Intellia Therapeutics by 2.7% in the second quarter. Wellington Management Group LLP now owns 43,484 shares of the company's stock valued at $736,000 after purchasing an additional 1,125 shares in the last quarter. Axxcess Wealth Management LLC grew its position in shares of Intellia Therapeutics by 6.1% in the first quarter. Axxcess Wealth Management LLC now owns 22,707 shares of the company's stock valued at $291,000 after purchasing an additional 1,308 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC grew its position in shares of Intellia Therapeutics by 6.1% in the third quarter. Cyndeo Wealth Partners LLC now owns 26,986 shares of the company's stock valued at $325,000 after purchasing an additional 1,556 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $11.42 on Friday. The company has a market cap of $1.60 billion, a PE ratio of -3.40 and a beta of 1.80. The stock's 50 day simple moving average is $12.27 and its 200-day simple moving average is $13.16. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.66 million during the quarter, compared to analysts' expectations of $12.98 million. During the same period in the previous year, the business earned ($0.98) earnings per share. The firm's revenue for the quarter was down 46.4% on a year-over-year basis. On average, equities research analysts anticipate that Intellia Therapeutics will post -3.21 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient's body.

Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.